Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
Phase 3
Completed
NCT05558410
| Condition | Acute Pain |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
|---|
| Status | Completed |
|---|
| Enrollment | 1,118 participants |
|---|
| Interventions | Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP) |
|---|
| Start date | Oct 10, 2022 |
|---|
| Completion date | Aug 25, 2023 |
|---|
| Results posted | Jul 1, 2025 |
|---|
Summary
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo
0 to 48 hours After First Dose of Study Drug · units on a scale
| Placebo | 70.1 ± 6.1 units on a scale |
|---|
| Suzetrigine (SUZ) | 118.4 ± 4.3 units on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.